Events

Speakers include Kevin Outterson, Executive Director of CARB-X. The rise of antimicrobial resistance and the corresponding lack of novel antibiotic development impacts the ability of physicians to provide appropriate care for patients. The greatest barriers to a robust antibiotic ecosystem are low return on investment (ROI) and limited market opportunities, in part due to payment […]

Moderator: Kevin Outterson, Executive Director, CARB-X, Professor of Law, Boston University Panel: Lars Rebien Sorensen, Chairman of the Novo Nordisk Foundation and Novo Holdings Jeremy Farrar, Director, Wellcome Trust Dr. Malin Grape, Head of Antibiotics Unit, The Public Health Agency of Sweden Thomas Cueni, Director General, IFPMA Jayasree K. Iyer, Executive Director, Access to Medicine Foundation […]

In this webinar, the following aspects will be presented: What are the most common techniques used to measure the extent of the risk of selecting for resistance when using a novel direct-acting antibacterial. What are the advantages and limitations of these techniques? What are some techniques that may be used to understand the origins of […]